Irreversible Cabozantinib-induced left ventricular systolic dysfunction, a potentially novel observation

Abstract

The case report describes the presentation of incident heart failure with reduced ejection fraction, following Cabozantinib chemotherapy. In contrast to previous cases, despite maximal medical therapy for this gentleman it became irreversible and contributed to his death. Hence the case illustrates the potential cardiotoxicity of Cabozantinib and reinforces the need for co-ordinated multi-disciplinary team care for such patients. Within existing cardio-oncology infrastructure, it may mean that such patients require enhanced echocardiographic surveillance.

Keywords:

• Heart failure
• cardiomyopathy
• renal cancer
• chemotherapy
• cabozantinib
• tyrosine kinase inhibitors

Disclosure statement

The above authors have nothing to disclose regarding this case report

Funding

There were no grants, contracts or other forms of financial support used in the production of this case report.

Disclaimer

The views expressed in this article are that of the authors and not an official position of the institution to which they belong.

Correction Statement

This article has been republished with minor changes. These changes do not impact the academic content of the article.